Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnSquareMore
Price
Data
About
BMY stock price forecast
News
Competitors
Tokenization
Crypto
FAQ
Bristol-Myers Squibb Company stock logo

Bristol-Myers Squibb Company

BMY·NYSE

Last updated as of 2026-02-12 08:00 EST. Stock price information is sourced from TradingView and reflects real-time market prices.

Insights
Calculator
News

BMY stock price change

On the last trading day, BMY stock closed at 60.62 USD, with a price change of -0.39% for the day.
Trade stock futures

About Bitget

The world's first Universal Exchange (UEX), enabling users to trade not only cryptocurrencies, but also stocks, ETFs, forex, gold, and real-world assets (RWA).
Learn more

BMY key data

Previous close60.62 USD
Market cap123.41B USD
Volume1.88M
P/E ratio17.53
Dividend yield (TTM)4.09%
Dividend amount0.63 USD
Last ex-dividend dateJan 02, 2026
Last payment dateFeb 02, 2026
EPS diluted (TTM)3.46 USD
Net income (FY)7.05B USD
Revenue (FY)48.19B USD
Next report dateApr 30, 2026
EPS estimate1.440 USD
Revenue estimate10.81B USD USD
Shares float2.03B
Beta (1Y)0.38
Tokenized stocks

Have you heard of tokenized stocks?

A new way to trade stocks — anytime, anywhere, 24/7.

Learn more

Bristol-Myers Squibb Company overview

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.
Sector
Health technology
Industry
Pharmaceuticals: Major
CEO
Christopher S. Boerner
Headquarters
Princeton
Website
bms.com
Founded
1933
Employees (FY)
-
Change (1Y)
-
Revenue / Employee (1Y)
-
Net income / Employee (1Y)
-

BMY Pulse

Daily updates on BMY stock prices, fund flows, and market news, generated by AI and reviewed by our team of analysts. Always DYOR.

• BMY Stock Price 24h change: -0.28%. From 60.77 USD to 60.60 USD.
• From a technical perspective, BMY exhibits a "bullish momentum with short-term consolidation": the long-term trend is positive with the price staying above its 50-day and 200-day moving averages (SMA), though short-term oscillators like the RSI (59.5) and Stochastics suggest it is approaching overbought territory after a recent 8.7% weekly surge. Key support is identified at $56.49, while resistance sits near $62.05.
• Bristol Myers Squibb reported Q4 2025 earnings of $1.26 EPS, missing estimates due to acquisition charges, but issued an upbeat 2026 guidance above Street expectations, citing growth in its immuno-oncology portfolio.
• The company launched the "Change the Target" campaign with Johnson & Johnson to address unmet needs in cardiovascular care, specifically targeting factor XIa to reduce stroke risk without increasing bleeding.
• BMY announced its 17th consecutive annual dividend increase to $0.63 per share, highlighting strong cash flow and commitment to shareholder returns despite "patent cliff" pressures on legacy drugs.
• The U.S. pharmaceutical industry is facing significant shifts as the government announced the next 15 high-cost drugs for price negotiations under the Inflation Reduction Act, including blockbusters from Gilead and Eli Lilly.
• New trade policies are reshaping the sector as the U.S. proposes pharmaceutical-specific tariffs of up to 150% by 2026, prompting major firms like Eli Lilly to announce massive $27 billion domestic manufacturing investments.
See more
about 21h ago
• BMY Stock Price 24h change: -1.37%. From $61.99 to $60.62. Price pressure followed a significant post-earnings rally, as the market digested a Q4 EPS miss despite a revenue beat and strong 2026 guidance.
• From a technical perspective, BMY shows a "bullish trend with short-term overbought signals": the stock maintains a technical rating of 8/10 with price above its 20-day ($60.65), 50-day ($57.93), and 200-day ($55.76) moving averages. However, a high RSI (~74-77) and Stochastics levels suggest the stock is in an overbought zone, making it prone to a temporary pullback or consolidation.
• Bristol Myers Squibb reported Q4 2025 revenue of $12.5B (beating estimates) and issued an upbeat 2026 revenue guidance of $46B–$47.5B, driven by a 15% growth in its new product portfolio.
• The company increased its quarterly dividend to $0.63 per share (approx. 4.2% yield), signaling confidence in cash flow despite the $0.39 EPS miss in the latest quarter.
• BMY received positive read-through and analyst price target raises (e.g., Guggenheim to $72) following successful clinical data from competitors in the stroke prevention space (FXIa inhibitors).
• Eli Lilly announced a $2.4 billion acquisition of Orna Therapeutics on February 9, highlighting the intense M&A activity and investment in next-generation cell and RNA therapies within the pharma sector.
• French pharmaceutical giant Servier announced a €15 million investment to launch a global single-pill platform "GATINN" to improve treatment adherence for chronic cardiometabolic diseases.
See more
about 1D ago

BMY stock price forecast

According to technical indicators for BMY stock, the price is likely to fluctuate within the range of 62.62–71.32 USD over the next week. Market analysts predict that the price of BMY stock will likely fluctuate within the range of 61.73–81.46 USD over the next months.

Based on 1-year price forecasts from 53 analysts, the highest estimate is 122.19 USD, while the lowest estimate is 69.82 USD.

For more information, please see the BMY stock price forecast Stock Price Forecast page.

Latest BMY stock news

Healthcare dealmakers head to San Francisco hoping for megamergers in 2026

101 finance2026-01-09 16:30:23

AbbVie secures agreement with the Trump administration on medication pricing in return for tariff reductions

101 finance2026-01-13 09:24:29

Factbox-Major deals involving U.S. drugmakers and biotechs over the past decade

101 finance2026-01-15 12:24:24

Bristol Myers collaborates with Microsoft to use AI technology for identifying lung cancer

101 finance2026-01-20 13:18:23

Biopharmaceutical company Janux Therapeutics partners with Bristol Myers Squibb

格隆汇2026-01-22 13:50:57

What’s Ahead in the Markets This Week: January Employment Data; Earnings Releases from Alphabet, Amazon, AMD, Disney, and Palantir

101 finance2026-02-01 11:06:48

January employment report, Alphabet and Amazon financial results, further impact from Warsh: Key events to follow this week

101 finance2026-02-01 12:51:28

Moderna Chief Medical Officer to Step Down

格隆汇2026-02-02 01:47:31

Bristol-Myers Squibb Earnings: Key Points to Watch for BMY

101 finance2026-02-04 03:21:37

Bristol-Myers Squibb expects 2026 revenue of approximately $46 billion to $47.5 billion, exceeding expectations

格隆汇2026-02-05 12:04:30

Bristol Myers: Fourth Quarter Earnings Overview

101 finance2026-02-05 12:18:35

Bristol Myers forecasts upbeat 2026, expecting Eliquis price cut to pay off

101 finance2026-02-05 12:36:39

What Are the Anticipated Outcomes for Royalty Pharma’s (RPRX) Fourth Quarter Earnings

101 finance2026-02-10 03:21:37

Organon Earnings: Key Points to Watch for OGN

101 finance2026-02-11 03:15:36

Bristol-Myers Squibb Company (BMY) Growth Portfolio Driving Earnings Growth

Finviz2026-02-12 09:45:39

With just a Bitget account, you can trade stocks and cryptocurrencies at the same time.

Join now!

FAQ

What is the stock price of Bristol-Myers Squibb Company?

BMY is currently priced at 60.62 USD — its price has changed by -0.39% over the past 24 hours. You can track the stock price performance of Bristol-Myers Squibb Company more closely on the price chart at the top of this page.

What is the stock ticker of Bristol-Myers Squibb Company?

Depending on the exchange, the stock ticker may vary. For instance, on NYSE, Bristol-Myers Squibb Company is traded under the ticker BMY.

What is the stock forecast of BMY?

We've gathered analysts' opinions on Bristol-Myers Squibb Company's future price. According to their forecasts, BMY has a maximum estimate of 606.20 USD and a minimum estimate of 121.24 USD.

What is the market cap of Bristol-Myers Squibb Company?

Bristol-Myers Squibb Company has a market capitalization of 123.41B USD.

What is P/E ratio (TTM)?

The P/E ratio (TTM) stands for price-to-earnings ratio (trailing twelve months). It is a historical valuation metric calculated using a company's earnings per share (EPS) over the most recent twelve consecutive months, reflecting the company's past profitability.

The P/E ratio measures the relationship between a stock's price and a company's profitability, and is often used as a basis for judging whether a stock is "cheap" or "expensive."

P/E ratio = market price (P) ÷ earnings per share (EPS), or P/E ratio = total market capitalization ÷ net profit attributable to shareholders

The interpretation of the P/E ratio (TTM) should always be considered alongside other factors and is mainly used for valuation comparisons rather than as a standalone indicator.

  • A lower P/E ratio (TTM) means investors are paying less for each unit of earnings. This may indicate that the stock is undervalued, or that the market has limited expectations for the company's future growth, such as in mature or slow-growing industries.
  • A higher P/E ratio (TTM) means investors are paying more for each unit of earnings. This often reflects expectations of strong future earnings growth, which is common among growth or technology stocks, though it may also suggest the stock is overvalued.
  • Comparison with peers: Compare the company's P/E (TTM) with the average or median P/E of other companies in the same industry. A significantly higher P/E may require further analysis to determine whether the company's high valuation is justified by stronger growth prospects or competitive advantages.
  • Comparison with historical levels: Compare the company's current P/E (TTM) with its own historical average (such as over the past 5 or 10 years) to assess whether the current valuation is at a historical high or low.
  • Comparison with the broader market: Compare the company's P/E (TTM) with major market indices (such as the S&P 500) to see how the market is valuing the company overall.

P/E ratios can vary widely across industries, and there is no single "ideal" P/E level. A reasonable P/E range depends on the industry, the company's growth potential, and the broader macroeconomic environment. Investment decisions should not rely solely on the P/E ratio (TTM) but should be based on a comprehensive analysis that includes company quality, growth prospects, and financial health.

Can I trade stocks on Bitget?

You can trade stocks on Bitget, but mainly through stock tokens and stock perps, rather than by directly buying or selling traditional stocks.

This approach reflects Bitget's vision as a Universal Exchange (UEX), designed to connect traditional financial markets with cryptocurrency markets.

Bitget currently offers the following stock-related trading formats:

1. Stock tokens (spot)

Nature: Stock tokens are digital tokens pegged to the price of specific traditional stocks (such as TSLAUSDT and NVDAUSDT) and are traded on Bitget's spot market.

Features: When you trade stock tokens, you are buying and holding tokens rather than owning the underlying traditional stocks.

  • The price of these tokens generally follows the price movements of the stocks they are pegged to, such as Tesla or Nvidia.
  • The advantage is that you can participate in the price movements of traditional financial assets, such as U.S. stocks, using cryptocurrencies (for example, USDT), without the need for a traditional brokerage account.

2. Stock perps

Nature: Bitget also offers USDT-margined perpetual futures, commonly referred to as stock perps, based on major U.S. blue-chip stocks such as Tesla and Meta.

Characteristics: Stock perps are derivative products that allow you to take a bullish or bearish view on the future price of an underlying stock through margin trading. These products typically support leverage, such as up to 25x.

It does not involve owning the underlying stock. Instead, profits and losses are settled based on price movements of the futures.

Important note: When trading stock perps on Bitget, you are participating in derivative markets within the cryptocurrency ecosystem. This is fundamentally different from purchasing publicly traded shares through a traditional brokerage, as you do not own equity in the underlying company.

Futures trading and the use of leverage involve high risk. Please ensure you fully understand the risks before trading.

If you wish to directly hold equity in traditional stocks and enjoy shareholder rights (such as receiving dividends), you must trade through a regulated traditional securities brokerage or brokerage platform.

What are the advantages of Bitget's stock perps?

Bitget's stock perps—typically perpetual futures based on stock tokens prices—are an innovative offering that allows cryptocurrency platforms to provide exposure to traditional financial markets.

Compared to traditional stock or futures trading, they offer several unique advantages, primarily due to the platform's trading infrastructure.

Bitget's stock perps, typically USDT-denominated derivatives, offer the following key advantages:

1. Trading convenience and global accessibility

  • 24/7 trading: Traditional stock markets, such as U.S. equity markets, operate during fixed trading hours. In contrast, cryptocurrency derivatives markets are typically open 24/7. This means investors can trade anytime, capitalizing on breaking news or market fluctuations.
  • Lower entry barriers and faster onboarding: Compared with traditional brokerages, which often require extensive identity verification and lengthy account setup processes, Bitget generally offers faster account onboarding. Users can trade using cryptocurrencies such as USDT, without the need for complex fiat deposit and withdrawal procedures.
  • Global accessibility: Users can access derivatives trading linked to globally recognized stocks via the Bitget platform, subject to applicable regulations.

2. Capital efficiency and high leverage

  • High leverage options: Stock perps typically offer higher leverage than traditional stock trading (for example, up to 25x). This allows traders to control larger positions with smaller margin requirements, improving capital efficiency.
    Note: While high leverage can amplify gains, it also amplifies losses proportionally.
  • Two-way trading: Traders can easily take both long and short positions. This means traders can potentially profit from market volatility whether stock prices rise or fall, provided the market direction is correctly anticipated.

3. Trading and settlement using cryptocurrency

  • USDT margin: Stock perps on Bitget typically use USDT (or other stablecoins) as the margin and settlement currency. For users who already hold cryptocurrency, there is no need to convert assets into fiat currency, allowing them to trade directly with stablecoins.
  • Efficient fund transfers: Crypto-based transfers and settlements are typically faster than traditional fiat systems, enabling more efficient global fund allocation.

4. Integration

One-stop platform: Bitget allows users to trade spot cryptocurrencies, crypto derivatives, and stock perps on a single platform, making it easier to manage different asset types in one place.

Risk warning:

While Bitget's stock perps offer several advantages, it is important to understand the associated risks.

  • High leverage risk: Leveraged trading can result in rapid loss of your entire margin.
  • No equity ownership: When trading stock perps, you do not own the underlying shares. As a result, you are not entitled to dividends or voting rights.
  • Market liquidity risk: Tokenized stock perps may have lower liquidity than their counterparts in traditional stock markets, especially outside regular trading hours.

In summary, Bitget's stock perps offer advantages such as greater trading flexibility, lower entry barriers, and higher capital efficiency.

What are the trading fees for Bitget stock perps?

Trading fees for Bitget stock perps (USDT-margined perpetual futures) mainly include transaction fees and funding rates.

Transaction fees:

Bitget offers limited-time fee promotions for stock perps (especially tokenized stock perps) from time to time to attract traders.

Standard reference rates: Under Bitget's standard futures fee structure, the taker fee is typically around 0.06%, while the maker fee is around 0.02%.

Current promotions for stock perps (important): To promote its stock perps products, Bitget is offering discounted transaction fees during Q4 2025, with taker fees as low as 0.006% and maker fees as low as 0.002%. There is also a limited-time promotion offering zero-fee trading for spot stock tokens.

Recommendation: Since promotional activities are subject to change or end at any time, please visit Bitget's official Fee overview or Announcement Center page for the latest and most accurate rates at the time of trading.

Funding rate:

The funding rate is a key mechanism in perpetual futures (including stock perps) that helps keep the futures price closely aligned with the spot price of the underlying asset. It is not a fee charged by the platform, but a periodic payment exchanged between long and short traders.

Funding rates fluctuate dynamically and are mainly driven by market sentiment and imbalances between long and short positions. Stock perps generally experience lower volatility than cryptocurrencies, so funding rates are often relatively low during stable market conditions. However, during earnings seasons or major positive or negative news events, heavy concentration of long or short positions—such as in high-growth technology stocks like Tesla or Nvidia—can create significant imbalances, causing funding rates to spike in the short term.

Funding payments are typically settled every 8 hours. If you close your position before the funding settlement time, no funding payment will be charged or received.

Funding rates are not fixed. If you hold a position for an extended period, high positive funding rates (for long positions) or high negative funding rates (for short positions) will affect your overall holding costs or potential returns. For this reason, it is important to monitor the funding rate in real time on the trading interface.

NYSE/
BMY